MetaCap

Invesco Biotechnology & Genome ETF (PBE)

NYSEARCA: PBEInvescoHealthETFUSD

96.90+2.64 (+2.80%)

At close: Oct 9, 3:15 PM ET · Delayed 15 min

PBE chart

Full chart

Key facts

Assets (AUM)
$423.52M
Holdings
10
Inception
Jun 23, 2005
Issuer
Invesco
Index tracked
—
Category
Health
52-week range
70.01 – 98.82
Volume / Avg
2.94K / 27.95K
Beta
—
Previous close
94.25

PBE ETF today

The Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund from Invesco in the Health category. It charges an expense ratio of 0.59%, or $59.00 per year on a $10,000 investment, and manages $423.5 million in assets. Its largest holding is Natera Inc (NTRA) at 6.23% of assets, and the top 10 positions make up 48.2% of the portfolio out of 10 holdings.

The fund's trailing dividend yield is 0.59% ($0.57 per share annually). PBE launched on Jun 23, 2005.

Summary generated from market data by MetaCap's automated system. Methodology

PBE top 10 holdings

PBE holdings by weight
#HoldingWeight
1NTRANatera Inc6.23%
2ILMNIllumina Inc6.17%
3BIIBBiogen Inc5.19%
4GILDGilead Sciences Inc5.08%
5AMGNAmgen Inc4.84%
6VRTXVertex Pharmaceuticals Inc4.80%
7RPRXRoyalty Pharma PLC Class A4.77%
8REGNRegeneron Pharmaceuticals Inc4.62%
9MRNAModerna Inc3.36%
10NVAXNovavax Inc3.17%

Top 10 holdings: 48.2% of assets.

PBE performance

1 week

+2.18%

PBE price return, excluding dividends.

ETFs similar to PBE

PBE ETF FAQ

What is the PBE price today?

PBE last traded at $96.90 as of Oct 9, 3:15 PM EDT, up 2.80% on the day.

What is PBE's expense ratio?

PBE has an expense ratio of 0.59%, which works out to about $59.00 per year for every $10,000 invested.

What are PBE's top holdings?

PBE's largest holdings are Natera Inc (6.23%), Illumina Inc (6.17%), Biogen Inc (5.19%), Gilead Sciences Inc (5.08%), Amgen Inc (4.84%). The top 10 make up 48.2% of the fund.

Does PBE pay a dividend?

Yes. PBE has a trailing dividend yield of 0.59%.

How big is PBE?

PBE has about $423.5 million in assets under management spread across 10 holdings.

Explore